scholarly journals A child with recurrent hemolytic uremic syndrome treated with fresh frozen plasma infusions and high-dose intravenous immunoglobulin therapy

1987 ◽  
Vol 10 (4) ◽  
pp. 408-414
Author(s):  
Jun-ichi Akatsuka ◽  
Sanpei Miyagawa ◽  
Koji Fujisawa ◽  
Hironori Nakamura ◽  
Shuji Nozaki ◽  
...  
Keyword(s):  
Hemolytic Uremic Syndrome ◽  
Intravenous Immunoglobulin ◽  
Immunoglobulin Therapy ◽  
Fresh Frozen Plasma ◽  
High Dose ◽  
Intravenous Immunoglobulin Therapy ◽  
Fresh Frozen ◽  
Uremic Syndrome ◽  
Frozen Plasma ◽  
Plasma Infusions

scholarly journals Clinical inefficacy of intravenous immunoglobulin therapy in low risk hemolytic uremic syndrome.

1999 ◽  
Vol 12 (2) ◽  
pp. 145-147
Author(s):  
Hirohiko Higashino ◽  
Minoru Kino ◽  
Akitoshi Nakamura ◽  
Gen Unishi ◽  
Masashi Hasui ◽  
...  
Keyword(s):  
Hemolytic Uremic Syndrome ◽  
Intravenous Immunoglobulin ◽  
Immunoglobulin Therapy ◽  
Low Risk ◽  
Intravenous Immunoglobulin Therapy ◽  
Uremic Syndrome

scholarly journals An Atypical Case of Shiga Toxin Producing-Escherichia Coli Hemolytic and Uremic Syndrome (STEC-HUS) in a Lung Transplant Recipient

2019 ◽  
Vol 2019 ◽  
pp. 1-3
Author(s):  
Louis Manière ◽  
Camille Domenger ◽  
Boubou Camara ◽  
Diane Giovannini ◽  
Paolo Malvezzi ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Kidney Function ◽  
Shiga Toxin ◽  
Lactate Dehydrogenase Level ◽  
Fresh Frozen Plasma ◽  
First Case ◽  
Maintenance Immunosuppression ◽  
Fresh Frozen ◽  
Uremic Syndrome ◽  
Frozen Plasma

We herein describe the first case of thrombotic microangiopathy (TMA) which was related to Shiga toxin producing-Escherichia Coli Hemolytic and Uremic Syndrome (STEC-HUS) after lung transplantation. His maintenance immunosuppression relied on tacrolimus plus mycophenolic acid. TMA was treated with plasma exchanges (PE) (fresh frozen plasma substitution). After five days of PE, platelets count and lactate dehydrogenase level normalized, whereas hemoglobin continued to gradually decrease and no improvement in kidney function was observed. After seven PE sessions, all TMA biological signs resolved. However, kidney function did not improve, and the patient still required chronic dialysis.

Congenital ADAMTS-13 deficiency presenting as life-threatening thrombosis during pregnancy

2021 ◽  
Vol 14 (8) ◽  
pp. e239901
Author(s):  
Faheema Hasan ◽  
Anshul Gupta ◽  
Dinesh Chandra ◽  
Soniya Nityanand
Keyword(s):  
Late Presentation ◽  
Fresh Frozen Plasma ◽  
Artery Thrombosis ◽  
Fresh Frozen ◽  
Life Threatening ◽  
A Disintegrin And Metalloproteinase ◽  
Thrombospondin Type 1 Repeats ◽  
Frozen Plasma ◽  
Plasma Infusions

Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease characterised by thrombocytopenia, microangiopathic haemolytic anaemia and microvascular thrombosis. Congenital TTP accounting for less than 5% of all TTP cases can have a late presentation in adulthood mostly triggered by predisposing factors such as infection, pregnancy and inflammation. We present a case of a 23-year-old woman who presented to us in the postpartum period with mesenteric artery thrombosis with infarcts and later was diagnosed as a case of TTP based on congenital a disintegrin and metalloproteinase with thrombospondin type 1 repeats 13 (ADAMTS-13) deficiency detected on ADAMTS-13 levels and gene sequencing. She was successfully managed initially with therapeutic plasma exchanges and is now on prophylactic fortnightly fresh frozen plasma infusions at 15 mL/kg body weight and continues to be in remission.

Sign in / Sign up

Export Citation Format

Share Document